Pharming Group reports on results of the 2024 Annual General Meeting of Shareholders
| PHAR Stock | USD 7.35 0.23 3.03% |
Slightly above 61% of Pharming Group's investor base is looking to short. The analysis of the overall investor sentiment regarding Pharming Group NV suggests that many traders are alarmed. Pharming Group's investing sentiment overview a quick insight into current market opportunities from investing in Pharming Group NV. Many technical investors use Pharming Group NV stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Pharming |
Leiden, the Netherlands, May 21, 2024 Pharming Group N.V. announces that at its Annual General Meeting of Shareholders held today, all proposals were approved.The shareholders approved the proposals to reappoint Ms. Barbara Yanni and Mr. Mark Pykett , upon binding recommendation of the Board of Directors, as Non-Executive Directors for a period of four years. In addition, the proposals for the
Read at finance.yahoo.com
 |
Pharming Group Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Pharming Group can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pharming Group Fundamental Analysis
We analyze Pharming Group's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pharming Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pharming Group based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Pharming Group is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Pharming Group NV Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pharming Group stock to make a market-neutral strategy. Peer analysis of Pharming Group could also be used in its relative valuation, which is a method of valuing Pharming Group by comparing valuation metrics with similar companies.
Peers
Pharming Group Related Equities
| GNTA | Genenta Science | 12.55 | ||||
| VRCA | Verrica Pharmaceuticals | 11.71 | ||||
| MLYS | Mineralys Therapeutics, | 4.71 | ||||
| RZLT | Rezolute | 4.18 | ||||
| MOLN | Molecular Partners | 3.19 | ||||
| ACRV | Acrivon Therapeutics, | 2.31 | ||||
| ANEB | Anebulo Pharmaceuticals | 2.14 | ||||
| OPT | Opthea | 1.83 | ||||
| LRMR | Larimar Therapeutics | 0.00 | ||||
| FENC | Fennec Pharmaceuticals | 0.50 | ||||
| ELYM | Eliem Therapeutics | 1.30 | ||||
| JANX | Janux Therapeutics | 3.35 | ||||
| PRTC | PureTech Health | 3.76 |
Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.